JANSSEN announces U.S. FDA approval of TREMFYA™ (GUSELKUMAB), the first approved biologic that selectively blocks interleukin (IL)-23, for the treatment of moderate-to-severe plaque psoriasis

  • TREMFYA™ is the first and only biologic approved that selectively blocks interleukin (IL)-23.
  • Seven out of ten patients receiving TREMFYA™ achieved at least 90 percent improvement in skin clearance at week 16.
  • Nearly three quarters of TREMFYA™-treated patients demonstrated at least 90 percent clearer skin at week 48.
  • TREMFYA™ demonstrated superior results in skin clearance compared with Humira®* (adalimumab) in head-to-head analyses at weeks 16, 24 and 48.

Published at Johnson & Johnson's official website at Latest Press Releases (https://www.jnj.com/media-center) on July 13, 2017.   Read more >>


Return to Pharma News